# Functional Brands Inc.: overview MEHA · OTC · CIK 1837254 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/meha.md) · [Financials](/companies/meha/financials.md) · [Filings](/companies/meha/filings.md) · [Insiders](/companies/meha/insiders.md) Latest reported revenue: [$1.9m](/filings/0001213900-26-089996.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-089996). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,396](/filings/0001213900-25-121689.md) | [1,680 d](/filings/0001213900-26-035675.md) | [1,590](/filings/0001213900-26-057934.md) | [1,833](/filings/0001213900-26-089996.md) | [1,694](/filings/0001213900-25-121689.md) | [1,495 d](/filings/0001213900-26-035675.md) | [1,646](/filings/0001213900-26-057934.md) | [1,871](/filings/0001213900-26-089996.md) | | Gross margin | % | [54.7%](/filings/0001213900-25-121689.md) | [58.9% d](/filings/0001213900-26-035675.md) | [54.5%](/filings/0001213900-26-057934.md) | [52.8%](/filings/0001213900-26-089996.md) | [57.7%](/filings/0001213900-25-121689.md) | [44.9% d](/filings/0001213900-26-035675.md) | [58.4%](/filings/0001213900-26-057934.md) | [59.9%](/filings/0001213900-26-089996.md) | | Operating margin | % | [(15.7%)](/filings/0001213900-25-121689.md) | [(8.1%) d](/filings/0001213900-26-035675.md) | [(2.0%)](/filings/0001213900-26-057934.md) | [(8.5%)](/filings/0001213900-26-089996.md) | [(4.6%)](/filings/0001213900-25-121689.md) | [(75.8%) d](/filings/0001213900-26-035675.md) | [(41.5%)](/filings/0001213900-26-057934.md) | [(70.6%)](/filings/0001213900-26-089996.md) | | Net margin | % | [(20.6%)](/filings/0001213900-25-121689.md) | [(16.5%) d](/filings/0001213900-26-035675.md) | [(8.0%)](/filings/0001213900-26-057934.md) | [(12.3%)](/filings/0001213900-26-089996.md) | [15.3%](/filings/0001213900-25-121689.md) | [57.0% d](/filings/0001213900-26-035675.md) | [(424.8%)](/filings/0001213900-26-057934.md) | [(140.6%)](/filings/0001213900-26-089996.md) | | Diluted EPS | $ per share | [(0.04)](/filings/0001213900-25-121689.md) | not reported | [(0.02)](/filings/0001213900-26-057934.md) | [(0.03)](/filings/0001213900-26-089996.md) | [0.04](/filings/0001213900-25-121689.md) | not reported | [(0.36)](/filings/0001213900-26-057934.md) | [(0.06)](/filings/0001213900-26-089996.md) | | Free cash flow | $k | not reported | [56.2 d](/filings/0001213900-26-035675.md) | not reported | not reported | not reported | [(2,750) d](/filings/0001213900-26-035675.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $k | [6,566](/filings/0001213900-26-035675.md) | [6,611](/filings/0001213900-26-035675.md) | | Gross margin | % | [54.9%](/filings/0001213900-26-035675.md) | [52.7%](/filings/0001213900-26-035675.md) | | Operating margin | % | [(3.5%)](/filings/0001213900-26-035675.md) | [(21.2%)](/filings/0001213900-26-035675.md) | | Net margin | % | [(8.5%)](/filings/0001213900-26-035675.md) | [11.5%](/filings/0001213900-26-035675.md) | | Diluted EPS | $ per share | [(0.08)](/filings/0001213900-26-035675.md) | [0.01](/filings/0001213900-26-035675.md) | | Free cash flow | $k | [0.1](/filings/0001213900-26-035675.md) | [(1,280)](/filings/0001213900-26-035675.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/meha/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Guardian Partners Inc.](/funds/1884799.md) | 2026-06-30 | $203 | 38,972 | | New +38,972 | ## Recent filings [All 114 filings](/companies/meha/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-17 | 16:01 ET | [8-K](/filings/0001213900-26-090736.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-090736 | | 2026-08-14 | 16:01 ET | [10-Q](/filings/0001213900-26-089996.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089996 | | 2026-07-02 | 16:16 ET | [8-K](/filings/0001213900-26-074986.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-074986 | | 2026-07-01 | 18:46 ET | [8-K](/filings/0001213900-26-073885.md) | 1.02 Termination of a material agreement | 0001213900-26-073885 | | 2026-06-15 | 08:00 ET | [8-K](/filings/0001213900-26-068518.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-068518 | | 2026-06-02 | 18:08 ET | [8-K](/filings/0001213900-26-063630.md) | 5.07 Shareholder vote results | 0001213900-26-063630 | | 2026-05-28 | 08:00 ET | [8-K](/filings/0001213900-26-061761.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-061761 | | 2026-05-22 | 10:14 ET | [8-K/A](/filings/0001213900-26-060362.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-060362 | | 2026-05-22 | 09:06 ET | [8-K](/filings/0001213900-26-060328.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-060328 | | 2026-05-20 | 17:00 ET | [8-K](/filings/0001213900-26-059603.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-059603 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-035675.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/86ccb2db-ad40-4fae-a10a-9a8ab5c31177) ## About the filer - CIK: 1837254 - Tickers: MEHA - Exchange: OTC - SIC code: 2833 Medicinal Chemicals & Botanical Products - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.